Drug intelligence / Profile preview

APO-2

Development stage: Phase 2
Lead developer: Aposcience
Administration: Topical

Overview

APO-2 is a biologic investigational medicinal product (IMP) developed by Aposcience AG. It is formulated as a dose-adjusted gel for topical administration and is currently being investigated for its safety and clinical efficacy in patients with diabetic foot ulcer.

Other names: APOSECapoptotic PBMC secretomeMARSYAS IIperipheral blood mononuclear cell secretome

Beyond the preview

Go deeper on APO-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APO-2.

Explore the full profile